Market Overview:
The global basal cell nevus syndrome drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of basal cell nevus syndrome, rising awareness about available treatments, and growing investments in research and development for new therapies. The global basal cell nevus syndrome drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into itraconazole, patidegib hydrochloride, REM-001 TG-1042 trifarotene Others). On the basis of application, the market is segmented into clinic hospital others).
Product Definition:
Basal Cell Nevus Syndrome Drug is a medication used to treat basal cell nevus syndrome, a condition characterized by the presence of numerous noncancerous (benign) skin growths on the body. These growths may be small or large, and can occur anywhere on the skin. Basal cell nevus syndrome drug may help to shrink or remove these growths.
Itraconazole:
Itraconazole, also known as N-4-trichloroethyl-1-(2,4-difluoropropyl)imidazole is a chemical compound used in the treatment of skin tumors. It is specifically used for the treatment of basal cell nevus syndrome (BCNS). The drug was first approved by the U.S.
Patidegib Hydrochloride:
Patidegib hydrochloride is a prescription medicine used for the treatment of basal cell nevus syndrome. It is manufactured by GlaxoSmithKline Pharmaceuticals, and was approved by the FDA in March 2009.
Application Insights:
Based on application, the market is segmented into a clinic, hospital and others. The other applications include research studies and industrial usage. The hospital segment dominated the market in 2017 owing to increasing prevalence of skin cancer as well as Basal Cell Nevus Syndrome (BCNS) cases across the globe. According to data published by WHO in 2018, an estimated 80% of patients with skin cancer are diagnosed outside hospitals while only 20% are diagnosed within hospitals. This factor is anticipated to fuel product demand in near future.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017. This is attributed to the local presence of key manufacturers and a high level of awareness pertaining to BCCNS diagnosis & treatment options, as well as various research activities undertaken by them in this region. In addition, increasing R&D investment by companies and government support are some other factors contributing toward market growth in this region.
Asia Pacific is expected to be one of the fastest-growing regions during the forecast period owing to an increase in healthcare expenditure levels coupled with rising patient affordability & accessibility, which has led to an increase in drug utilization rates over time; hence driving market growth during forecast period from 2018 till 2030 (estimated CAGR).
Growth Factors:
- Increasing incidence of Basal Cell Nevus Syndrome (BCNS) due to changing lifestyle and environmental factors.
- Growing awareness about the early diagnosis and treatment of BCNS among patients and healthcare professionals.
- Rising demand for better quality of life among BCNS patients, which is driving the adoption of novel therapeutics.
- increasing research funding for development of new drugs for the treatment of BCNS 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Basal Cell Nevus Syndrome Drug Market Research Report
By Type
Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene, Others
By Application
Clinic, Hospital, Others
By Companies
Adgero Biopharmaceuticals Holdings Inc, Galderma SA, Mayne Pharma Group Ltd, PellePharm Inc, Transgene SA, Adgero Biopharmaceuticals Holdings Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Basal Cell Nevus Syndrome Drug Market Report Segments:
The global Basal Cell Nevus Syndrome Drug market is segmented on the basis of:
Types
Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adgero Biopharmaceuticals Holdings Inc
- Galderma SA
- Mayne Pharma Group Ltd
- PellePharm Inc
- Transgene SA
- Adgero Biopharmaceuticals Holdings Inc
Highlights of The Basal Cell Nevus Syndrome Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Itraconazole
- Patidegib Hydrochloride
- REM-001
- TG-1042
- Trifarotene
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Basal Cell Nevus Syndrome Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Basal cell nevus syndrome (BCNS) is a skin disorder that affects the skin and hair. It is a type of cancer. BCNS can be caused by the sun, HPV, or other factors. Drugs used to treat BCNS include topical treatments such as corticosteroids and retinoids, systemic treatments such as chemotherapy or radiation therapy, and surgery.
Some of the major players in the basal cell nevus syndrome drug market are Adgero Biopharmaceuticals Holdings Inc, Galderma SA, Mayne Pharma Group Ltd, PellePharm Inc, Transgene SA, Adgero Biopharmaceuticals Holdings Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Basal Cell Nevus Syndrome Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Basal Cell Nevus Syndrome Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Basal Cell Nevus Syndrome Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Basal Cell Nevus Syndrome Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Basal Cell Nevus Syndrome Drug Market Size & Forecast, 2020-2028
4.5.1 Basal Cell Nevus Syndrome Drug Market Size and Y-o-Y Growth
4.5.2 Basal Cell Nevus Syndrome Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Itraconazole
5.2.2 Patidegib Hydrochloride
5.2.3 REM-001
5.2.4 TG-1042
5.2.5 Trifarotene
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Basal Cell Nevus Syndrome Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Basal Cell Nevus Syndrome Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Itraconazole
9.6.2 Patidegib Hydrochloride
9.6.3 REM-001
9.6.4 TG-1042
9.6.5 Trifarotene
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Itraconazole
10.6.2 Patidegib Hydrochloride
10.6.3 REM-001
10.6.4 TG-1042
10.6.5 Trifarotene
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Itraconazole
11.6.2 Patidegib Hydrochloride
11.6.3 REM-001
11.6.4 TG-1042
11.6.5 Trifarotene
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Itraconazole
12.6.2 Patidegib Hydrochloride
12.6.3 REM-001
12.6.4 TG-1042
12.6.5 Trifarotene
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Itraconazole
13.6.2 Patidegib Hydrochloride
13.6.3 REM-001
13.6.4 TG-1042
13.6.5 Trifarotene
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Basal Cell Nevus Syndrome Drug Market: Competitive Dashboard
14.2 Global Basal Cell Nevus Syndrome Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Adgero Biopharmaceuticals Holdings Inc
14.3.2 Galderma SA
14.3.3 Mayne Pharma Group Ltd
14.3.4 PellePharm Inc
14.3.5 Transgene SA
14.3.6 Adgero Biopharmaceuticals Holdings Inc
